Communiqués

20/07/20 PROTEO INC : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K) AQ
10/07/20 PROTEO INC : Submission of Matters to a Vote of Security Holders (form 8-K) AQ
05/06/20 PROTEO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) AQ
12/05/20 PROTEO INC : Other Events (form 8-K) AQ
07/05/20 PROTEO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) AQ
30/03/20 PROTEO INC : Other Events (form 8-K) AQ
03/03/20 PROTEO INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K) AQ
08/11/13 Proteo Inc : Patient recruitment and treatment in Elafin CABG Phase II clinical trial completed PU
16/08/11 PROTEO INC : Proteo, Inc. / Proteo Biotech AG: EMPIRE-Study recruits first coronary bypass patients PU
18/06/10 PROTEO INC : Proteo, Inc./ Proteo Biotech AG: Proteo's Elafin Will Be Tested at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) BU
30/11/-1 PROTEO : Proteo, Inc./Proteo Biotech AG: Clinical Study in Harvard Reveals Elafin Deficiency in Acute Respiratory Distress Syndrome (ARDS) BU
30/11/-1 PROTEO : Inc./Proteo Biotech AG - Minapharm/Rhein Minapharm Biogenetics SAE: Approval for a Phase II Clinical Trial with Elafin in Kidney Transplantation BU
30/11/-1 PROTEO : Proteo, Inc./Proteo Biotech AG: Start of the Phase II clinical trial with Elafin BU
Aucun résultat pour cette recherche